相关实验视频

Updated: Jan 13, 2026

Single-Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy Model in Mice

Single-Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy Model in Mice

Published on: February 10, 2023

一步式与两步式十二指肠切换后,从高风险肥胖症中解脱的时间:倾向性得分单一中心分析:一个倾向性得分单一中心分析

Javier Osorio¹, David Merino², Lucia Sobrino³

¹Hospital Clínic de Barcelona, Barcelona, Spain. josorio@clinic.cat.

Obesity surgery

|January 6, 2026

概括

与高BMI患者的两步方法相比,直接的十二指管开关 (DS) 提供了优越的长期无疾病状态和体重控制. 这两种减肥手术方法的安全性概况仍然相似.

科学领域:

腹腔外科手术是什么意思
代谢手术是一种代谢手术.
外科手术的结果

背景情况:

十二指肠切换 (DS) 可以作为一阶段的直接手术或在袖子胃切除术后的两步方法进行.
存在有限的对比数据,比较这些DS方法之间的长期无疾病结果.

研究的目的:

为了比较直接 (单阶段) 和双阶段十二指肠切换 (DS) 程序之间的无疾病时间和安全性.
评估在重度肥胖患者中不同DS方法的长期疗效和安全性.

主要方法:

倾向性得分匹配分析将75名直接DS患者与75名双步DS患者进行了比较.
匹配标准包括年龄,性别和基线体重指数 (BMI).
评估结果包括并发症,死亡率,严重腹,营养不良,随访率,体重减轻和3年和5年的无疾病状态.

主要成果:

直接和双阶段DS都表现出可比的安全性,短期和长期并发症率相似,没有死亡率,严重腹或营养不良.
直接的DS在5年内显示出明显优异的无疾病状态 (66.7% vs 57.1%) 和更持久的体重控制 (BMI < 35 kg / m2: 88.2% vs 71.4%).
直接DS也导致了更大的总体重减轻 (45.4%与42.0%相比).

结论:

直接十二指肠切换 (DS) 是一个安全有效的选择,患者的BMI>50 kg/m2.
与两步方法相比,直接DS实现了更长的高风险无疾病状态和更持久的体重控制.
直接DS的安全概况与两个步骤的DS程序相似.

关键词:

腹腔外科手术是什么意思十二指关节的开关低吸收性手术是一种低吸收性手术.肥胖问题肥胖问题修订性减肥手术是重复性的.

更多相关视频

Sleeve Gastrectomy in Mice using Surgical Clips

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice

Published on: October 18, 2024

相关概念视频

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Obesity

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...